Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
February 14, 2024 08:05 ET
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event
February 01, 2024 08:35 ET
|
Autonomix Medical, Inc.
Live moderated webcast with members of the Autonomix management team on Wednesday, February 7th at 10:00 AM ET THE WOODLANDS, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc....
Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
January 31, 2024 08:45 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
January 30, 2024 09:05 ET
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...
Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ
January 29, 2024 08:05 ET
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE)...
Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
January 26, 2024 16:05 ET
|
Autonomix Medical, Inc.
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...
Autonomix Medical, Inc. Successfully Completes Preclinical Safety Study to Support Program Advancement into First-in-Human Clinical Study to Treat Pancreatic Cancer Pain Through Transvascular Ablation
January 12, 2024 10:00 ET
|
Autonomix Medical, Inc.
Patented two-fold technology in development to locate, ablate and confirm successful ablation of specific nerves for pain management and other uses All safety inputs met with no reported...
Autonomix Medical, Inc. Completes Formation of Engineering Development Team and Provides Project Update
January 11, 2024 10:00 ET
|
Autonomix Medical, Inc.
Appointment of Marco Bedoya, a proven leader in medical device mechanical engineering, as Director of Product Development Engagements secured with preeminent firms to drive design and development...
Autonomix Medical, Inc. to Present at the Startup Investing Webinar
January 11, 2024 09:00 ET
|
Autonomix Medical, Inc.
Live webcast roundtable discussion featuring Autonomix, Knightscope, and Infinity Fuel on Thursday, January 11th at 2:00 PM ET THE WOODLANDS, TX, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix...
Autonomix Medical, Inc. Provides Business Overview and Highlights Upcoming Milestones
January 04, 2024 10:00 ET
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Patented two-fold technology that can potentially detect problematic neural signals and ablate nerves in one simple...